FDA to review Pfizer plaque-psoriasis test drug XELJANZ
Pfizer said on Wednesday that the U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ, a medication for treating moderate to severe chronic plaque psoriasis. Read More »